Recombinant adeno-associated virus (AAV) and lentiviral vectors (LV) are vehicles for direct delivery of therapeutic genes to patients' cells. In the coming years, the use of AAV and LV in clinical applications is projected to increase exponentially. Maximizing production of safe and effective viral vectors is essential to match this growing need. In this talk, we present optimization strategies for the transfection step of vector production to generate high titers of both AAV and LV using TransIT-VirusGEN® Transfection Reagent. The VirusGEN® AAV and LV Transfection Kits push the limits of high-titer virus production, which expand the manufacturing capabilities for gene and cell therapies.
1. Identify critical parameters for optimizing viral vector production using VirusGEN®
2. Explain how VirusGEN® supports development and manufacturing of gene and cell therapies